


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

RESIGNATION AND APPOINTMENT OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 20 April 2018:-

1. RESIGNATION OF DIRECTORS

Mr. Homer Sun (“**Mr. Sun**”) has resigned as a non-executive Director in order to devote more time to other business commitments and engagements.

Dr. Guo Feng (“**Dr. Guo**”) has resigned as an executive Director as he is assigned to be the head of a subsidiary of the Company which is principally engaged in research and development, clinical and management work. Dr. Guo will remain as a Group Vice President of development.

Mr. Sun and Dr. Guo have respectively confirmed that they have no disagreement with the Board and there is no matter relating to their resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

2. APPOINTMENT OF EXECUTIVE DIRECTORS

Dr. Zhang Jionglong (“**Dr. Zhang**”) has been appointed as an executive Director and chief investment officer of the Company.

Ms. Chen Yan Ling (“**Ms. Chen**”) has been appointed as an executive Director.

Dr. Zhang Jionglong

Dr. Zhang Jionglong, aged 56, joined the Company’s management in the Capacity as the head of the Group’s investment department since April 2018. He is in charge of the Group’s investment and mergers and acquisitions. He was first appointed to the Board as a non-executive Director on 18 May 2006 until 8 December 2017. Dr. Zhang has more than 10 years of experience as a medical doctor. From 1983 to 1992, Dr. Zhang worked as a medical doctor in Shenzhen City People’s Hospital, one of the largest hospitals in Shenzhen City, PRC. Dr. Zhang obtained a Graduate Certificate in Medical Treatment from Shantou Medical College, PRC (汕頭醫學專科學院) (now known as Shantou University Medical College (汕頭大學醫學院)) in 1983. In 1992, Dr. Zhang was conferred the professional title of Chief Physician by the Shenzhen City Title Conferment Reform Leadership Group (深圳市職稱改革領導小組).

Save as disclosed above Dr. Zhang did not hold any directorship in any listed public companies during the past three years.

Dr. Zhang is not connected with nor has any relationship with any other Directors, senior management or the substantial or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) of the Company.

As at the date of this announcement, Dr. Zhang was deemed to be interested in 5,907,898,697 shares of the Company (the “**Shares**”) within the meaning of Part XV of the Securities and Futures Ordinance (“**SFO**”).

Dr. Zhang has not yet entered into any director service agreement with the Company. No designated length of service has been agreed between Dr. Zhang and the Company. Dr. Zhang will hold office until the next general meeting of the Company and will be subject to retirement by rotation and re-election in accordance with the Bye-laws of the Company. The remuneration of Dr. Zhang will be determined by the remuneration committee under the Board with reference to his duties, responsibilities and experience, and prevailing market conditions.

Save as disclosed above, there is no other information relating to Dr. Zhang that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules nor there is any other matter relating to the appointment of Dr. Zhang required to be brought to the attention of the shareholders of the Company.

Ms. Chen Yan Ling

Ms. Chen Yan Ling, aged 40, is the person in charge of the secretariat of the Group's Board of Directors. Her main responsibilities are to manage all matters relating to the board of directors. She joined the Group in March 2006 and has served in the Group for 12 years. Joined the Group since 2006, she has been working as an assistant to the Chairman of the Group assisting in managing the board secretariat and Hainan Sihuan Pharmaceutical Co., Ltd. She is in charge of the listing, daily management and investor relationship of the Group, etc. Prior to joining the Group, she worked as an English translation officer at the information centre of Guangzhou Tourism Bureau in 2001. In 2002, she worked as an assistant to general manager at Yip's Ink & Chemicals (Zhongshan) Company Ltd. (葉氏油墨(中山)有限公司) and was in charge of the daily management of the general manager's office as well as planning and promotion. In 2004, she worked as an assistant to the president of Guangzhou Culturecom Company Ltd. (廣州文化傳信有限公司) and was in charge of the daily management of the president's office, planning and budgeting, media resources integration and development, maintenance, etc.

Ms. Chen obtained an undergraduate degree in English from Hunan University in 2001. In June 2009, she participated in a training class for board secretaries held by Shenzhen Stock Exchange, passed the examination and obtained qualification as a board secretary from the Shenzhen Stock Exchange.

Ms. Chen did not hold any directorship in any listed public companies during the past three years.

Ms. Chen is not connected with nor has any relationship with any other Directors, senior management or the substantial or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

As at the date of this announcement, Ms. Chen did not have any interests in the Shares within the meaning of Part XV of the SFO.

Ms. Chen has not yet entered into any director service agreement with the Company. No designated length of service has been agreed between Ms. Chen and the Company. Ms. Chen will hold office until the next general meeting of the Company and will be subject to retirement by rotation and re-election in accordance with the Bye-laws of the Company. The remuneration of Ms. Chen will be determined by the remuneration committee under the Board with reference to her duties, responsibilities and experience, and prevailing market conditions.

Save as disclosed above, there is no other information relating to Ms. Chen that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules nor there is any other matter relating to the appointment of Ms. Chen required to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its appreciation to Mr. Sun and Dr. Guo for their contributions to the Company during their tenure in office and to welcome Dr. Zhang and Ms. Chen for joining the Board.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 20 April 2018

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Mr. Choi Yiau Chong, Dr. Zhang Jionglong and Ms Chen Yan Ling; the non-executive director of the Company is Mr. Kim Jin Ha; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Mr. Zhu Xun.